Asia Pharmaceuticals and Healthcare Report Q2 2017
|出版日期||內容資訊||英文 37 Pages
|亞洲的醫藥品、醫療產業 (季度更新報告) Asia Pharmaceuticals and Healthcare Report Q2 2017|
|出版日期: 2017年04月26日||內容資訊: 英文 37 Pages||
本報告提供亞洲各國的製藥產業及醫療產業相關分析，地區整體產業規模的實際成果值、預測值 (過去5年、今後10年份) 估計，產業的課題 (風險) 和未來性的商機 (利潤) 相關評估，域內各地區詳細趨勢，主要企業簡介等資訊彙整，為您概述為以下內容
BMI View:Acts undertaken by US President Donald Trump will shape the Asia Pacific's pharmaceutical sectors. The withdrawal of the US from the Trans-Pacific Partnership is particularly significant, passing up an opportunity to introduce strong intellectual property protections which would have had ramifications beyond the original seven Asia Pacific member states. Trump's push to encourage the domestic manufacture of drugs will also affect pharmaceutical exporters in the region, with India being the most exposed - 38% of its total medicine exports went to the US in 2015.
The Asia Pacific average in our Innovative Pharmaceuticals Risk/Reward Index (RRI) outperforms the global average by a small but significant margin. This is because the region comprises of two of the world's largest pharmaceutical markets, and is boosted by the significant growth potential of several emerging markets.